Related Experiment Video

Updated: Feb 10, 2026

A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction
05:28

A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

17.7K

lncRNA DLEU1 contributes to tumorigenesis and development of endometrial carcinoma by targeting mTOR

Yuping Du1, Lili Wang2, Shuo Chen2

  • 1Department of Obstetrics and Gynecology, The Third Affiliated Hospital of Guangzhou Medical University, Key Laboratory for Major Obstetric Diseases of Guangdong Province, and Key Laboratory of Reproduction and Genetics of Guangdong Higher Education Institute in Guangdong Province, Guangzhou, China.

Molecular Carcinogenesis
|May 11, 2018
PubMed

Insights

Long non-coding RNA DLEU1 (lncRNA DLEU1) promotes endometrial carcinoma by activating the PI3K/AKT/mTOR pathway. This finding offers potential for new diagnostic biomarkers and targeted therapies for endometrial cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Gene Expression

Background:

  • Long non-coding RNAs (lncRNAs) are implicated in various cancers.
  • The role of lncRNA DLEU1 in endometrial carcinoma (EC) remains unexplored.
  • Understanding lncRNA DLEU1's function in EC is crucial for potential therapeutic strategies.

Purpose of the Study:

  • To investigate the expression, function, and mechanism of lncRNA DLEU1 in endometrial carcinoma.
  • To determine if lncRNA DLEU1 acts as a biomarker or therapeutic target in EC.

Main Methods:

  • Quantitative reverse transcription PCR (qRT-PCR) for lncRNA DLEU1 expression analysis.
  • Cell viability, migration, invasion, and apoptosis assays in EC cell lines.
  • Xenograft nude mouse models for in vivo tumorigenesis assessment.
  • RNA immunoprecipitation (RIP) and Western blot to identify molecular interactions and pathway activation.

Main Results:

  • lncRNA DLEU1 was significantly upregulated in endometrial carcinoma tissues and cell lines.
  • Overexpression of lncRNA DLEU1 enhanced EC cell proliferation, migration, and invasion while reducing apoptosis.
  • lncRNA DLEU1 directly binds to mTOR, activating the PI3K/AKT/mTOR signaling pathway.
  • lncRNA DLEU1 promoted tumor growth in vivo.

Conclusions:

  • lncRNA DLEU1 plays a critical role in promoting endometrial carcinoma progression.
  • The lncRNA DLEU1/mTOR/PI3K/AKT pathway is a key mechanism driving EC tumorigenesis.
  • lncRNA DLEU1 represents a promising biomarker and therapeutic target for endometrial carcinoma.
Keywords:
PI3K/AKT/mTORendometrial carcinomalncRNA DLEU1mTORtumorigenesis

More Related Videos

Author Spotlight: Investigating Liver Cancer Pathogenesis Using Patient-Derived Organoids07:25

Author Spotlight: Investigating Liver Cancer Pathogenesis Using Patient-Derived Organoids

Published on: August 18, 2023

2.6K
Generation of Multicellular Human Primary Endometrial Organoids09:20

Generation of Multicellular Human Primary Endometrial Organoids

Published on: October 4, 2019

11.7K

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
10.0K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

3.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
Binet's Contribution to Measures of Intelligence01:23

Binet's Contribution to Measures of Intelligence

Alfred Binet, along with his student Théophile Simon, was tasked by the French Ministry of Education in 1904 to create a method for identifying students who struggled to learn through conventional classroom instruction. This initiative aimed to address overcrowding by placing such students in specialized schools. Binet and Simon developed an intelligence test comprising 30 tasks, ranging from simple commands, like touching one's nose or ear, to more complex tasks, such as drawing...
1.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.6K
Wechsler's Contribution to Measures of Intelligence01:23

Wechsler's Contribution to Measures of Intelligence

David Wechsler, a psychologist who worked with World War I veterans, developed a significant IQ test in 1939 called the Wechsler-Bellevue Intelligence Scale. This test was innovative because it combined several subtests that measured both verbal and nonverbal skills, reflecting Wechsler's belief that intelligence is a global capacity involving purposeful action, rational thinking, and effective interaction with the environment. This test later evolved into the Wechsler Adult Intelligence...
2.1K